For the Inventor, By the Inventor

Enter assignee name

Rottapharm Biotech S.r.l.

USPTO Granted Patents = 15

CIPO Patents = 20

EPO Patents = 26

Forward Citations = 16

Loading Chart...

Loading Chart...

61 inventors (with patents filed for the assignee):

Lucio C Rovati (15 out of 57 patents)

Luigi Piero Stasi (7 out of 8 patents)

Gianfranco Caselli (5 out of 26 patents)

4. Roberto Artusi (3 out of 10 patents)

5. Manuela Borriello (3 out of 3 patents)

6. Sabrina Pucci (3 out of 4 patents)

7. Michela Visintin (2 out of 5 patents)

8. Fabrizio Colace (2 out of 3 patents)

9. Antonio Giordani (2 out of 29 patents)

10. Benedetta Buzzi (2 out of 2 patents)

11. Tiziana Piepoli (2 out of 4 patents)

12. Filippo Magaraci (2 out of 2 patents)

13. Riccardo Chiusaroli (1 out of 1 patent)

14. Stefano Mandelli (1 out of 8 patents)

15. Gabriele Ugolini (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12433875 - (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification (2025-10-07),

2. 12404245 - Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof (2025-09-02),

3. 11718582 - (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist (2023-08-08),

4. 11590114 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2023-02-28),

5. 10125121 - FYN kinase inhibitors (2018-11-13),

6. 9631029 - Anti-ADAMTS-5 antibody, derivatives and uses thereof (2017-04-25),

7. 9498478 - Spiro aminic compounds with NK1 antagonist activity (2016-11-22),

8. 9365654 - Anti-TrkA antibodies, derivatives and uses thereof (2016-06-14),

9. 9181279 - [object Object] (2015-11-10),

10. 9174977 - 2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders (2015-11-03),

11. 9162979 - 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors (2015-10-20),

12. 9120824 - [object Object] (2015-09-01),

13. 9062033 - Chemical compounds (2015-06-23),

14. 8859608 - Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction (2014-10-14),

15. 8828987 - Pyridine amide derivatives as EP4 receptor antagonists (2014-09-09),

Rottapharm Biotech S.R.L. is a leading biotech company, specializing in the development and production of innovative pharmaceutical products. With a strong commitment to research and development, Rottapharm Biotech aims to improve global healthcare by delivering cutting-edge treatments for various medical conditions. Through its state-of-the-art facilities and dedicated team of scientists, the company strives to create and commercialize reliable and effective therapeutic solutions. Visit their website for more information and to discover their portfolio of groundbreaking products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

15 Patents

#2 in Monza

#608 in Italy

#38,649 in the World

Rottapharm Biotech S.r.l.

Forward Citations = 16

61 inventors:

Lucio C Rovati (15 out of 57 patents)

Luigi Piero Stasi (7 out of 8 patents)

Gianfranco Caselli (5 out of 26 patents)

4. Roberto Artusi (3 out of 10 patents)

5. Manuela Borriello (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…